Immunosuppressive therapies for inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 12, 2014, Pages 3146-3152

  Zenlea, Talia ^a   Peppercorn, Mark A ^b  

^a BROWN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Crohn's disease; Immunosuppressives; Inflammatory bowel disease; Tumor necrosis factor inhibitors; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BIOLOGICAL PRODUCT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 1; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; USTEKINUMAB; VEDOLIZUMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; ARTICLE; CANCER RECURRENCE; CLINICAL FEATURE; CROHN DISEASE; DRUG MECHANISM; FEVER; FLU LIKE SYNDROME; HEPATITIS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; LIVER TOXICITY; LUPUS LIKE SYNDROME; NAUSEA; NAUSEA AND VOMITING; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEPSIS; TREATMENT OUTCOME; TUBERCULOSIS; TUMOR REGRESSION; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; DRUG COMBINATION; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES;

BIOLOGICAL PRODUCTS; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897003313     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i12.3146     Document Type: Article

References (61)

1. Stein RB, Lichtenstein GR. Medical therapy for Crohn's disease: the state of the art. Surg Clin North Am 2001; 81: 71-101, viii [PMID: 11218170]
2. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubin-sky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastro-enterol 2011; 106 Suppl 1: S2-25; quiz S26 [PMID: 21472012 DOI: 10.1038/ajg.2011.58]
3. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15-29 [PMID: 19949430 DOI: 10.1038/nrgastro.2009.203]
4. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-2078 [PMID: 19923578 DOI: 10.1056/ NEJMra0804647]
5. Vermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25: 3-12 [PMID: 17229216 DOI: 10.1111/j.1365-2036.2006.03134.x]
6. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954; 2: 375-378 [PMID: 13182220]
7. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 630-642 [PMID: 21407186 DOI: 10.1038/ajg.2011.64]
8. Feagan BG, Alfadhli A. Methotrexate in inflammatory bowel disease. Gastroenterol Clin North Am 2004; 33: 407-20, xi [PMID: 15177546 DOI: 10.1016/j.gtc.2004.03.001]
9. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercap-topurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-987 [PMID: 6102739 DOI: 10.1056/ nejm198005013021801]
10. Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol 2005; 39: 557-569 [PMID: 16000921]
11. Jones JL, Loftus EV. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Infamm Bowel Dis 2007; 13: 1299-1307 [PMID: 17600819 DOI: 10.1002/ibd.20211]
12. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64: 753-767 [PMID: 18506437 DOI: 10.1007/s00228-008-0478-6]
13. Regueiro MD. Update in medical treatment of Crohn's disease. J Clin Gastroenterol 2000; 31: 282-291 [PMID: 11129268]
14. Chaparro M, Ordás I, Cabré E, Garcia-Sanchez V, Bastida G, Peñalva M, Gomollón F, García-Planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-Sepulcre M, Hi-nojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Mon-toro MA, Barreiro-Deacosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Infamm Bowel Dis 2013; 19: 1404-1410 [PMID: 23665964 DOI: 10.1097/MIB.0b013e318281f28f]
15. Cummings JR, Keshav S, Travis SP. Medical management of Crohn's disease. BMJ 2008; 336: 1062-1066 [PMID: 18467414 DOI: 10.1136/bmj.39547.603218.AE]
16. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercap-topurine. Gut 2005; 54: 1121-1125 [PMID: 16009685 DOI: 10.1136/gut.2004.049460]
17. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F. Lym-phoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-1625 [PMID: 19837455 DOI: 10.1016/s0140-6736(09)61302-7]
18. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefts outweigh the risk of lymphoma. Gastroenterology 2000; 118: 1018-1024 [PMID: 10833475]
19. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-28.e1-5 [PMID: 21708105 DOI: 10.1053/j.gastro.2011.06.050]
20. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, Sampat S, Mendizabal M, Lin MV, Lichten-stein GR. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36-41. e1 [PMID: 20888436 DOI: 10.1016/j.cgh.2010.09.016]
21. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4: 266-273 [PMID: 12106498]
22. Bentin J. Mechanism of action of cyclosporin in rheumatoid arthritis. Clin Rheumatol 1995; 14 Suppl 2: 22-25 [PMID: 8846650]
23. Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994; 330: 1846-1851 [PMID: 8196727 DOI: 10.1056/nejm199406303302602]
24. Stange EF, Modigliani R, Peña AS, Wood AJ, Feutren G, Smith PR. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. Gastroenterology 1995; 109: 774-782 [PMID: 7657105]
25. Brynskov J, Freund L, Rasmussen SN, Lauritsen K, de Muckadell OS, Williams N, MacDonald AS, Tanton R, Molina F, Campanini MC. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321: 845-850 [PMID: 2671739 DOI: 10.1056/nejm198909283211301]
26. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993; 88: 646-649 [PMID: 8480725]
27. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroen-terol 1999; 94: 1587-1592 [PMID: 10364029 DOI: 10.1111/ j.1572-0241.1999.01149.x]
28. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-135 [PMID: 7797011]
29. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gas-troenterology 2012; 142: 257-65.e1-3 [PMID: 22062358 DOI: 10.1053/j.gastro.2011.10.032]
30. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Sch-reiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infiximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 [PMID: 12047962 DOI: 10.1016/s0140-6736(02)08512-4]
31. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Long-term outcome of treatment with infiximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500 [PMID: 18832518 DOI: 10.1136/ gut.2008.155812]
32. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infiximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405 [PMID: 10228190 DOI: 10.1056/nejm199905063401804]
33. Sands BE, Anderson FH, Bernstein CN, Chey WY, Fea-gan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infiximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885 [PMID: 14985485 DOI: 10.1056/NEJMoa030815]
34. Cullen G, Vaughn B, Ahmed A, Peppercorn MA, Smith MP, Moss AC, Cheifetz AS. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. Infamm Bowel Dis 2012; 18: 691-696 [PMID: 21648022 DOI: 10.1002/ibd.21783]
35. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lich-tenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476 [PMID: 16339095 DOI: 10.1056/NEJMoa050516]
36. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infiximab. Gastroenterol-ogy 2009; 137: 1250-1260; quiz 1520 [PMID: 19596014 DOI: 10.1053/j.gastro.2009.06.061]
37. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Sch-reiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 674-688 [PMID: 18532990 DOI: 10.1111/j.1365-2036.2008.03753.x]
38. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-630 [PMID: 16678077 DOI: 10.1016/ j.cgh.2006.03.002]
39. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimum-ab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33; quiz 591 [PMID: 16472588 DOI: 10.1053/ j.gastro.2005.11.030]
40. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-1239 [PMID: 17299059 DOI: 10.1136/gut.2006.106781]
41. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infiximab: a randomized trial. Ann Intern Med 2007; 146: 829-838 [PMID: 17470824]
42. Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fstulas in patients with Crohn's disease. Gut 2009; 58: 940-948 [PMID: 19201775 DOI: 10.1136/gut.2008.159251]
43. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-1111. e2 [PMID: 22326435 DOI: 10.1053/j.gastro.2012.01.035]
44. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalim-umab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787 [PMID: 21209123 DOI: 10.1136/gut.2010.221127]
45. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfeld R, Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238 [PMID: 17634458 DOI: 10.1056/NEJMoa067594]
46. Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfeld R, Sandborn WJ. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010; 8: 600-609 [PMID: 20117244 DOI: 10.1016/ j.cgh.2010.01.014]
47. Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfeld R, Sandborn WJ. Randomised clinical trial: cer-tolizumab pegol for fstulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 185-193 [PMID: 21083671 DOI: 10.1111/ j.1365-2036.2010.04509.x]
48. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286-92; quiz e24 [PMID: 23200982 DOI: 10.1016/j.cgh.2012.11.011]
49. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Tar-gan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925 [PMID: 16267322 DOI: 10.1056/NEJMoa043335]
50. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panac-cione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tu-lassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterol-ogy 2007; 132: 1672-1683 [PMID: 17484865 DOI: 10.1053/ j.gastro.2007.03.024]
51. Kane SV, Horst S, Sandborn WJ, Becker B, Neis B, Moscan-drew M, Hanson KA, Tremaine WJ, Bruining DH, Faubion WA, Pardi DS, Harmsen WS, Zinsmeister AR, Loftus EV. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. In-famm Bowel Dis 2012; 18: 2203-2208 [PMID: 22419661 DOI: 10.1002/ibd.22943]
52. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P. Progressive multifocal leukoencephalopathy after natali-zumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-368 [PMID: 15947080 DOI: 10.1056/NEJMoa051586]
53. Verbeeck J, Van Assche G, Ryding J, Wollants E, Rans K, Vermeire S, Pourkarim MR, Noman M, Dillner J, Van Ranst M, Rutgeerts P. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopa-thy? Gut 2008; 57: 1393-1397 [PMID: 18436577 DOI: 10.1136/ gut.2007.145698]
54. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gas-troenterology 2014; 146: 85-95; quiz e14-5 [PMID: 23735746 DOI: 10.1053/j.gastro.2013.05.048]
55. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterol-ogy 2014; 146: 96-109.e1 [PMID: 23770005 DOI: 10.1053/ j.gastro.2013.06.010]
56. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Sch-reiber S, Lichtiger S, Feagan BG. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-1528 [PMID: 23075178 DOI: 10.1056/NEJMoa1203572]
57. Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, Feagan BG. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1691-1699 [PMID: 23591599 DOI: 10.1097/ MIB.0b013e318281f538]
58. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Cohen A, Bitton A, Baker J, Dubé R, Landau SB, Vandervoort MK, Parikh A. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha-4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-1377 [PMID: 18829392 DOI: 10.1016/j.cgh.2008.06.007]
59. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710 [PMID: 23964932 DOI: 10.1056/NEJMoa1215734]
60. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rut-geerts P. Infiximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492]
61. Panccione R, Ghosh S, Middleton S, Marquez JR, Khalif I, Flint L, van Hoogstraten H, Zheng H, Danese S, Rutgeerts PJ. Infliximab, azathioprine, or infliximab azathioprine for treatment of moderate to severe ulcerative colitis: The UC SUCCESS trial. Gastroenterology 2011; 150: S-134 [DOI: 10.1016/S0016-5085(11)60548-9]